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Abstract: Krabbe disease is an autosomal recessive leukodystrophy caused by pathogenic variants
in the galactocerebrosidase (GALC) gene. GALC activity is needed for the lysosomal hydrolysis
of galactosylceramide, an important component of myelin. While most patients are infants, older
patients are also diagnosed. Starting in 1970, a diagnosis could be made by measuring GALC activity
in leukocytes and cultured cells. After the purification of GALC in 1993, the cDNA and genes were
cloned. Over 260 disease-causing variants as well as activity lowering benign variants have been
identified. While some pathogenic variants can be considered “severe,” others can be considered
“mild.” The combination of alleles determines the type of Krabbe disease a person will have. To
identify patients earlier, newborn screening (NBS) has been implemented in several states. Low
GALC activity in this screening test may indicate a diagnosis of Krabbe disease. Second tier testing
as well as neuro-diagnostic studies may be required to identify those individuals needing immediate
treatment. Treatment of pre-symptomatic or mildly symptomatic patients at this time is limited to
hematopoietic stem cell transplantation. Treatment studies using the mouse and dog models have
shown that combining bone marrow transplantation with intra-venous gene therapy provides the
best outcomes in terms of survival, behavior, and preservation of normal myelination in the central
and peripheral nervous systems. With earlier diagnosis of patients through newborn screening and
advances in treatment, it is hoped that more patients will have a much better quality of life.
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Krabbe disease or globoid cell leukodystrophy is an autosomal recessive disorder
resulting in defective myelination in the central and peripheral nervous systems. It has
an incidence of about 1 in 100,000 births in the United States and Northern Europe. The
incidence can vary greatly between countries and between different ethnic groups [1]. Most
of the diagnosed individuals have the infantile form with onset between 0 and 12 months,
followed by a rapid downhill course, and leading to death by about two years of age when
untreated. Individuals presenting in the late infantile and adult periods are also diagnosed.
They currently make up about 10–20% of the patients diagnosed with Krabbe disease.
Their clinical course is slower, with some surviving into the seventh decade without
treatment [1]. As the birth demographics are changing in the United States, it appears that
more individuals with later-onset forms are being identified. Much information regarding
the incidence is being learned from the individuals identified by newborn screening.
The past 100 plus years of research on Krabbe disease has brought us from patient
descriptions to the latest research on newborn screening and to the verge of new therapies
for treating patients more effectively. The earliest published description of patients with
globoid cell leukodystrophy was by Dr. Knud Krabbe in 1916 [2]. He described five infants
who clearly showed the phenotype of infantile Krabbe disease. In 1940 [3], his name was
first given to this autosomal recessive disease, although the patients in that paper may
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not have had Krabbe disease. The presence of the characteristic globoid cells in the white
matter of the brain were described in 1924 [4]. These cells were later noted to contain a
monoglycosylated ceramide and to be present in myelin [5]. In 1970, Malone [6] and Suzuki
and Suzuki [7] showed that the enzyme responsible for the lysosomal hydrolysis of galactosylceramide, called galactocerebrosidase (GALC) or galactosylceramide beta-galactosidase,
was deficient in patients with Krabbe disease. That was an important breakthrough, since
it permitted rapid diagnosis using blood or cultured skin cells without the need for a brain
biopsy. However, there was a paradox, since patients with most lysosomal disorders, like
Gaucher disease, Niemann–Pick disease, and Tay–Sachs disease, store the undegraded
substrate of the missing enzyme, the nervous tissues of these patients did not store large
amounts of galactosylceramide. The biosynthesis of galactosylceramide is catalyzed by
the enzyme UDP-galactose:ceramide galactosyltransferase (CGT), which adds galactose
from uridine diphospho-galactose to ceramide and other lipid acceptors. The activity of
this enzyme is highest during the period of most rapid myelination, which starts in utero
in humans and at about 10 days in the mouse. The enzyme is most active in the cells
making myelin, the oligodendrocytes in brain, and Schwann cells in the peripheral nervous
system. CGT also catalyzes the transfer of galactose to sphingosine to make psychosine,
but there is little evidence that this compound is acylated to make galactosylceramide.
Psychosine may be a dead-end pathway and is hydrolyzed into galactose and sphingosine
in individuals who have normal GALC activity, but not in individuals who have Krabbe
disease. There is much evidence showing that psychosine is toxic when added to almost
all cell types [8–15]. While the amount of psychosine produced is relatively small, there is
enough to be toxic to myelinating cells, resulting in their death and a defect in myelination.
In fact, in 1980, Svennerholm et al. [16] called Krabbe disease a psychosine lipidosis. More
about the significance of elevated psychosine as a second-tier test in the diagnosis of Krabbe
disease has recently been published [17,18].
2. GALC Purification and Cloning of the Gene
The purification of human GALC proved to be a difficult undertaking requiring more
than 20 years of research. During that time, this laboratory attempted to purify GALC from
different tissues, including placenta, liver, and brain. These tissues were extracted and
subjected to many purification steps without GALC, reaching sufficient purity for protein
sequencing or antibody production. After noting that the activities of other lysosomal
enzymes could be measured in urine, we found we could also measure GALC activity in
urine. Of course, the activity was quite low, but it was already in solution and did not
require the extraction from solid tissues with thousands of other components. Through
trial and error, a small amount of pure GALC was purified from 150 L of urine [19]. We
found that GALC was produced as an 80 kDa precursor that was proteolytically cleaved
into 30 and 50 kDa subunits. The partial amino acid sequence was obtained, and from
that information, the GALC cDNA of humans was cloned [20]. Further studies led to
the organization of the GALC gene [21]. Following this, the GALC cDNAs of dogs [22],
twitcher mice [23], and rhesus monkeys [24] were also cloned, and the disease-causing
variants in these species were identified.
3. Early Diagnostic Studies and Mutation Analysis
Our laboratory has always had two overlapping components: diagnosis and research.
There was no physical separation between the co-workers, and findings were interchanged
between each component of the laboratory. Interesting patients fueled research, and
research findings aided the diagnostic testing. By 1993, before we published on the cloning
of the human cDNA, we had already diagnosed over 175 patients with Krabbe disease
by enzymatic testing, indicating that molecular analysis is not required for an accurate
diagnosis. While most patients were infants, older patients were also diagnosed. With
the sequence of the human GALC cDNA available, mutation analysis of patients with
Krabbe disease could be undertaken. Initially, all of the sequencing was done manually
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via Sanger, and the nucleotide sequences were read from X-ray films [25]. In 1995, we first
identified the 30 kb deletion as a common pathogenic variant in infantile patients with
Krabbe disease [26]. At that time, we called it 502/del because the large deletion always
occurred with a C>T transition polymorphism at cDNA position 502 (using the legacy
numbering system). This deletion eliminates the coding region of seven exons that includes
all of the 30 kDa subunit and about 15% of the coding region of the 50 kDa subunit. In
this laboratory, Dr. Luzi located the 50 and 30 positions of the deletion, starting within the
large intron 10, and going past the end of the GALC gene [27]. A rapid test for the 30 kb
deletion was developed. When this mutation is found to be homozygous, the individual
will always present in infancy, but when the second allele provides even a small amount of
GALC activity, then the phenotype can be mild. Further studies showed that the 30 kd del
was also heterozygous in some late-onset patients, including adults with Krabbe disease.
4. Relationship between Measured GALC Activity and Phenotype
The question of how much GALC activity is enough to either prevent the disease
entirely or delay the onset until later in life is difficult to answer. The measurement
of GALC activity in easily obtained tissues, such as blood or cultured skin fibroblasts,
does not provide information about the activity in nervous tissues, where it is needed to
maintain normal myelination. The method for measuring GALC activity using radiolabeled
galactosylceramide in this laboratory has been in use since 1972. The GALC activities
measured in leukocytes and cultured skin fibroblasts from infantile and late-onset patients
are not statistically different from each other. However, newer methods for measuring
GALC activity may be better at accurately detecting very low levels of GALC activity [28].
While there is little doubt that late-onset patients have some small amount of GALC activity,
it may be difficult to measure in the tissues available for diagnostic studies. Moreover,
activity measured in leukocytes and/or fibroblasts may not reflect the activity in nervous
tissues where it is needed. In addition to low GALC activity, there may be a need for
another insult to bring on the onset of clinical features in older patients with Krabbe
disease. Insults could include an infection that affects the nervous system or immune
system, a blow to the head, a hypoxic event, etc. Could some people with genetically
different immune systems and APOE types be more susceptible to later-onset disease than
others?
While measurement of low GALC activity in leukocytes has been the method of
choice for rapid diagnosis of Krabbe disease since 1970, it is not perfect, which became
clear as more testing was being done. It is known from the earliest days of testing that
there were completely normal individuals with quite low GALC activity [29]. Once the
GALC gene was cloned, it became apparent that there were variants that lowered the
measured GALC activity but did not cause disease even when inherited in both copies
of the gene or together with a pathogenic variant. However, when some polymorphic
variants are in cis with certain variants, that allele becomes disease causing [30,31]. For
example, the expression of two common polymorphic variants alone and together in COS1
cells shows the effects on GALC activity (Figure 1). The presence of such polymorphisms
makes carrier testing by enzyme analysis nearly impossible because both the “normal”
range and “carrier” range are very wide. This has been brought home with the advent of
newborn screening (NBS), which measures GALC activity in dried blood spots soon after
birth [32]. As low GALC activity can be measured in dried blood spots both in individuals
who will develop infantile-onset Krabbe disease and later-onset Krabbe disease, as well
as individuals who have multiple copies of enzyme-lowering polymorphisms, additional
testing is required to identify those infants needing immediate attention. The best method
appears to be measurement of psychosine in dried blood spots or red blood cells. A dried
blood spot psychosine value over 10 nmol/L indicates that the individual probably will
have an infantile onset, and the parents should be counseled appropriately regarding
treatment options. Values between 2 and 9 nmol/L may indicate a later-onset form. Values
under 2 nmol/L indicate that the individual probably will not develop Krabbe disease.
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have an infantile onset, and the parents should be counseled appropriately regarding
treatment options. Values between 2 and 9 nmol/L may indicate a later-onset form. Values
under 2 nmol/L indicate that the individual probably will not develop Krabbe disease. In
individuals with a psychosine concentration over 2 nmol/L, mutation analysis and neuroIn individuals with a psychosine concentration over 2 nmol/L, mutation analysis and
diagnostic studies may be indicated, but it is not a first priority [17,18].
neuro-diagnostic studies may be indicated, but it is not a first priority [17,18].
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each allele. While a “severe” allele may contribute little or no activity, a “mild” allele may
have 2–3% of normal activity, which is enough to delay onset for many years. Therefore,
inheriting two copies of a “mild” allele should provide 4–6% of normal activity, which may
be enough to prevent the onset of disease for life.
Table 1. Common Pathogenic Variants in the GALC Gene.
Effect

Comments b

GGC>AGC

p.G41S (p.G57S)

Mild, Southern Italy

GGC>GAC

p.G95D (p.G111D)

Severe

c.286A>G (c.334A>G)

ACT>GCT

p.T96A (p.T112A)

Mild c

Ex 7

c.635 del + ins (c.683 del + ins)

del 12, ins3

del 5 aa + ins 2 aa

Severe, Japanese,
Korean

Ex 8

c.809G>A (c.857G>A)

GGC>GAC

p.G270D (p.G286D)

Mild

Ex 8

c.860C>T (c.908C>T)

TCC>TTC

p.S287F (p.S303F)

Severe

Ex 9

c.908A>G (c.956A>G)

TAT>TGT

p.Y303C (p.Y319C)

Mild d

In10-end

30 kb deletion

30 kb del

Short mRNA

Severe

Ex 11

c.1138C>T (c.1186C>T)

CGG>TGG

p.R380W (p.R396W)

Severe

Ex 13

c.1424 delA (c.1472 delA)

TAAGG>TAGG

FS, PS

Severe

Ex 14

c.1538 C>T (c.1586C>T)

ACG>ATG

p.T513M (p.T529M)

Severe

Ex 15

c.1652A>C (c.1700A>C)

TAC>TCC

p.Y551S (p.Y567S)

Severe

Ex 16

c.1853T>C) (c.1901T>C)

TTA>TCA

p.L618S (p.L634S)

Mild (Asian)

Location

Nucleotide Change in cDNA

Codon Change

Ex 1

c.121G>A (c.169G>A) a

Ex 4

c.284G>A (c.332G>A)

Ex 4

a

Location of variants and protein changes in the original numbering system are shown first; those in parentheses are based on a start
codon 48 nucleotides longer. b The comments reflect the best information available from published and unpublished data. c May only
be disease causing when the p.I562T polymorphism is present on the same allele. d May only be disease causing when the other allele is
considered “severe” or when a polymorphism is present on the same allele. Note: Many disease-causing mutations found in the GALC
gene also contain polymorphisms in the same copy of the gene. Abbreviations: aa = amino acids; del = deletion; ins = insertion; c. = cDNA;
p. = protein; FS = frame shift; PS = premature stop.

Table 2. Common Polymorphic Variants in the GALC gene.
Location

Nucleotide Change in cDNA

Codon Change

Effect

Comments b

Ex 4

c.502C>T (c.550C>T) a

CGT>TGT

p.R168C (p.R184C)

The 30 kb deletion
always has this
polymorphism

Ex 6

c.694G>A (c.742G>A)

GAT>AAT

p.D232N (p.D248N)

Ex 8

c.865A>G (c.913A>G)

ATC>GTC

p.I289V (p.I305V)

Japanese

Ex 14

c.1637T>C (c.1685T>C)

ATA>ACA

p.I546T (p.I562T)

Very common

a

Location of mutations and protein changes in the original numbering system are shown first (legacy); those in parentheses are based on a
start codon 48 nucleotides longer. b The comments reflect the best information available from published and unpublished data.

Of course, variant type (missense, premature stop, large and small deletions, insertions
plus insertion/deletions, splice junction changes) and location can have a wide range of
effects on the GALC protein and its activity. GALC with a missense variant can have many
possible effects or none. Depending on the change produced by the variant, GALC may not
be processed properly in the endoplasmic reticulum (ER), the Golgi, or the lysosome [33]. If
the variant causes the GALC to get misfolded and held up in the ER, it could be degraded
by cellular quality-control mechanisms. If the mutation is in or near the active site, activity
could be lowered because of inefficient binding of substrate or saposin activating factor. All
disease-causing missense variants result in much lower GALC activity than the “normal”
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sequence, ranging from almost zero to 2–3% of normal. Very low activity may be difficult
to accurately measure.
Variants resulting in a premature stop codon will usually result in very low GALC
activity in the truncated protein. With some premature stop codons, it is possible that a
small amount of mutant protein is produced. The effects of variants occurring at exonintron splice junctions can be variable. Usually, they result in exon skipping or inclusion of
some intronic sequence with unpredictable effects on the measured GALC activity. While it
will probably result in very low GALC activity, there may be production of a small amount
of protein, and this could lead to later-onset disease. For example, the c.195 G>C mutation
occurs at an exonic splice site (before intron 1) and does not change the amino acid. Since
the patients who are homozygous for this variant are all late-onset [34], there must be some
active enzyme produced.
6. Management of Individuals Confirmed to Be at Risk for Developing Krabbe
Disease
Management of individuals confirmed to have or to develop Krabbe disease will
depend on their age and clinical status at the time of diagnosis. Individuals having
significant neurologic deficits and clinical features at the time of diagnosis will need
supportive care. However, the goal of NBS is to identify infants who will develop Krabbe
disease before significant pathological damage to the nervous systems has occurred and to
prepare them for treatment. Parental attitudes towards the value of NBS for Krabbe disease
can be variable [35]. At this time, the standard of care in pre-symptomatic infants and mildly
affected later-onset patients is hematopoietic stem cell transplantation (HSCT) [36,37].
Initially, patients were treated using blood stem cells from bone marrow; however, more
recently, HSCs isolated from umbilical cord blood are being used. This greatly improves
the chances of finding a suitable human leukocyte antigen match for a given patient. While
this treatment has been shown to increase the lifespan of treated infantile patients, almost
all present with difficulty walking and have problems with expressive language by the end
of the first decade of life [38]. The walking difficulties appear to be due to a failure of HSCT
to adequately correct the peripheral nervous system. Attempts to improve the protocol for
treating human patients are being made using the available animal models.
7. Treatment of the Animal Models of Krabbe Disease
Three naturally occurring animal models of Krabbe disease with mutations in the
GALC gene have been described [22–24]. Obviously, because of cost and ease of breeding,
the twitcher (twi) mouse model has been used the most in treatment trials. These mice have
one nucleotide change (p.W339X) resulting in a premature stop codon [23]. In 1984 Yeagar
et al. [39] performed bone marrow transplantation (BMT) on ten-day-old twi mice, which
extended their lives from 40 days to about 80 days. X-irradiation was used to prepare
the mice for the BMT. They reported partial repair of the demyelination in the PNS, but
no improvement of the pathology in the CNS. Both treated and untreated twi mice had
tremors beginning at about post-natal day 20 (PND20). While these studies showed some
extension of life and some pathological improvement with HSC treatment, it clearly was
not good enough. Many other papers have been published describing other treatments,
including enzyme replacement therapy, injection of neural progenitor cells, gene therapy
via different routes of administration, substrate reduction therapy, chemical chaperone
therapy, small molecule therapy including anti-inflammatory drugs, and combinations
of these approaches [40–58]. These different treatments have resulted in variable degrees
of success. Some of these trials only resulted in minimal extension of life and some had
significant side effects and pathological events, including hepatocellular carcinoma. Other
treatments involving multiple injections into the brain, BMT without myeloablation of the
recipient, and use of toxic chemicals for substrate reduction probably will not be used in
human patients.
At this time, studies in the mouse model indicate that AAV vectors carrying the GALC
cDNA offer the best option for use in a human trial, probably in combination with the
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current “standard of care” HSCT [57]. While the HSCT does provide some GALC activity
to the tissues, it also provides some anti-inflammatory effects to nervous tissues [41,58]. At
least in twi mice, intra-venous (iv) injection of AAVrh10-mGALC alone results in normal
or supra-normal GALC in all tissues, including the brain, spinal cord, and sciatic nerves,
within 48 h of injection [57]. There is normal myelination in the CNS and PNS in these
mice. However, combining a single iv injection of AAVrh10-GALC with BMT results in a
great synergist effect with some mice living a normal lifespan [57]. The treated mice show
normal myelination in the central and peripheral nervous systems. There is no evidence for
neoplastic changes in the liver as reported by other laboratories using different methods of
treatment. To get closer to a human trial, timing and dosing of the treatment were studied
to obtain the optimum conditions [57]. Lowering the dose of AAVrh10-GALC resulted in
shorter lifespans than previously published, and a higher dose of the viral vector increased
the average lifespan even further, although it was not statistically significant. Delaying
the injection of viral vector from one day after the BMT to five and 10 days after the BMT
resulted in similar positive results. However, delaying both the BMT and the viral injection
by 20 days resulted in a shorter average lifespan in the treated mice. This indicates that
damage has occurred in the nervous systems that cannot be corrected. These studies help
to provide a timetable for treatment, at least in the mouse model. In addition to greatly
extending the lives of treated mice, there was maintenance of body weight and strength,
normal myelination in the brain and sciatic nerves, and elimination of the tremor associated
with twi mice. More recent studies in twi mice have shown that BMT may not be required
if high dose AAVrh10-GALC is given iv early in life [59]. This treatment eliminates some of
the side effects of the drugs needed before BMT.
As part of the preclinical studies, the Food and Drug Administration required toxicology studies in rats to see if this viral vector causes serious pathological changes in
any tissues. Only minimal pathological changes were observed in liver and other tissues.
Studies in a few dogs with Krabbe disease using BMT plus iv AAVrh10-canine GALC
showed very positive results that also correlate with the dose of the viral vector [60]. While
untreated affected dogs live only about 17 weeks, a 2-year-old dog treated with BMT plus
high dose iv AAVrh10-canine GALC behaved completely normally and had normal myelination in the CNS and PNS. Therefore, combining HSCT, the standard of care in human
patients, with an iv injection of AAVrh10-humanGALC could result in a great improvement
in the quality of life for individuals treated early in their disease. Such treatment requires
early diagnosis made possible by NBS and rapid confirmatory testing. At this time, two
companies, Forge Biologics and Passage Bio, are starting to recruit asymptomatic and
mildly symptomatic patients for gene therapy trials [see clinicaltrials.gov accessed on
30 January 2021]. With this information, families can be presented with treatment options
as quickly as possible before significant pathological changes occur.
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